1024 679 ORI Capital

Kymab is a Cambridge UK, based therapeutic antibody company focusing on generating high-quality fully humanized antibodies to treat challenging diseases. Since its incorporation in 2010, Kymab has raised $220 million in equity financing from leading investors to enable it to develop the Kymouse™ platform and create a portfolio of therapeutic antibody assets.